期刊文献+

甘精胰岛素与预混胰岛素治疗2型糖尿病的疗效与安全性比较 被引量:4

下载PDF
导出
摘要 目的:比较甘精胰岛素与预混胰岛素治疗2型糖尿病的临床疗效及安全性。方法:选择58例T2DM患者,使用口服降糖药(OAD)但血糖控制不达标(HbA1Cd>7.5%),随即分为两组:甘精组30例,预混组28例。分别采用每晚10点注射甘精胰岛素、三餐前口服阿卡波糖和预混胰岛素(诺和锐30)早晚餐前皮下注射。治疗目标空腹血糖(FPG)<6.0 mmol/L,餐后2 h血糖(2hPG)<10.0 mmol/L,治疗12周。结果:两组患者FPG、2 h PG、HbA1C均低于治疗前,但甘精组FPG较预混组下降明显(P<0.05),达到FPG<6.0 mmol/L(63%vs50%,P<0.05)和HbA1C<7.0%(60%vs46%,P<0.05)的更多。低血糖的比例低(P<0.05)。结论:每晚1次甘精胰岛素皮下注射及餐前口服阿卡波糖治疗T2DM,使血糖控制良好,低血糖发生率低。
出处 《吉林医学》 CAS 2013年第25期5181-5182,共2页 Jilin Medical Journal
  • 相关文献

参考文献3

  • 1《中国2型糖尿病防治指南》,中华医学会糖尿病学会,2007:25.
  • 2姜文清,杨莉萍,马捷,邹定,李金娥.长效基础胰岛素类似物甘精胰岛素[J].中国新药杂志,2005,14(6):778-781. 被引量:60
  • 3春江.胰岛素与口服降糖药联合治疗2型糖尿病[J].中国医学论坛报,2004,8:19.

二级参考文献18

  • 1宁光.发挥胰岛素效能治疗达标[N].中国医学论坛报,2003,10-23(16).
  • 2Kupecz D, Berardinelli C. Drug and device approval highlights from 2001 [J]. Nurse Pract ,2002,27(2) :15 - 16,21 -23.
  • 3Levien TL, Baker DE,White JR Jr, et al. Insulin glargine:a new basal insulin [ J ]. Ann Pharmacother, 2002, 36 ( 6 ): 1019 -1027.
  • 4李萍.新胰岛素制剂研究和临床应用[EB/OL].http://www.511511. com. cn/news/documents/20030605171357862. htm -22k,2003-05-15/2003-12-20.
  • 5Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro[ J ].Diabetes, 2000,49 (12): 2142 - 2148.
  • 6Heise T, Bott S, Rave K, et al. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes [ J ]. Diabet Med, 2002,19 (6): 490 -495.
  • 7Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of125I- labeled insulin glargine (HOE 901 ) in healthy men:comparison with NPH insulin and the influence of different subcutaneous injection sites[J]. Diabetes Care,2000,23(6):813- 819.
  • 8Mudaliar S, Mohideen P, Deutsch R, et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles[J ].Diabetes Care, 2002,25 (9): 1597 - 1602.
  • 9Owens DR, Griffiths S. Insulin glargine (Lantus) [J ]. Int J Clin Pract, 2002,56(6) :460 - 466.
  • 10Yki Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J ]. Diabetes Care ,2000,23(8): 1130 - 1136.

共引文献59

同被引文献19

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部